Stock Track | Duality Biotherapeutics Plummets 5.04% Intraday on Widened 2025 Loss and Revenue Decline

Stock Track03-24

Duality Biotherapeutics (09606.HK) shares plummeted 5.04% during intraday trading on Tuesday, following the release of its full-year 2025 financial results.

The biopharmaceutical company reported a significant widening of its loss attributable to owners, which reached RMB2.59 billion for 2025 compared to a loss of RMB1.05 billion in the previous year. Concurrently, the company's revenue declined to RMB1.85 billion from RMB1.94 billion in 2024.

These disappointing financial figures, highlighting both increased losses and a drop in sales, are the primary drivers behind the sharp sell-off in the stock. The company also announced the appointment of a new Chief Financial Officer in a separate filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148394372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 11:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148394372","market":"sg","top_or_hot":-1,"title":"Stock Track | Duality Biotherapeutics Plummets 5.04% Intraday on Widened 2025 Loss and Revenue Decline","media":"Stock Track","content":"<p>Duality Biotherapeutics (09606.HK) shares plummeted 5.04% during intraday trading on Tuesday, following the release of its full-year 2025 financial results.</p><p>The biopharmaceutical company reported a significant widening of its loss attributable to owners, which reached RMB2.59 billion for 2025 compared to a loss of RMB1.05 billion in the previous year. Concurrently, the company's revenue declined to RMB1.85 billion from RMB1.94 billion in 2024.</p><p>These disappointing financial figures, highlighting both increased losses and a drop in sales, are the primary drivers behind the sharp sell-off in the stock. The company also announced the appointment of a new Chief Financial Officer in a separate filing.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Duality Biotherapeutics Plummets 5.04% Intraday on Widened 2025 Loss and Revenue Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Duality Biotherapeutics Plummets 5.04% Intraday on Widened 2025 Loss and Revenue Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-24 11:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Duality Biotherapeutics (09606.HK) shares plummeted 5.04% during intraday trading on Tuesday, following the release of its full-year 2025 financial results.</p><p>The biopharmaceutical company reported a significant widening of its loss attributable to owners, which reached RMB2.59 billion for 2025 compared to a loss of RMB1.05 billion in the previous year. Concurrently, the company's revenue declined to RMB1.85 billion from RMB1.94 billion in 2024.</p><p>These disappointing financial figures, highlighting both increased losses and a drop in sales, are the primary drivers behind the sharp sell-off in the stock. The company also announced the appointment of a new Chief Financial Officer in a separate filing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1148394372","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148394372","pubTimestamp":1774321752,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Duality Biotherapeutics (09606.HK) shares plummeted 5.04% during intraday trading on Tuesday, following the release of its full-year 2025 financial results.The biopharmaceutical company reported a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"个股赛道|Duality Biotherapeutics盘中暴跌5.04%因2025年亏损扩大和营收下滑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"Duality Biotherapeutics (09606.HK) shares plummeted 5.04% during intraday trading on Tuesday, following the release of its full-year 2025 financial results.The biopharmaceutical company reported a significant widening of its loss attributable to owners, which reached RMB2.59 billion for 2025 compared to a loss of RMB1.05 billion in the previous year. Concurrently, the company's revenue declined to RMB1.85 billion from RMB1.94 billion in 2024.These disappointing financial figures, highlighting both increased losses and a drop in sales, are the primary drivers behind the sharp sell-off in the stock. The company also announced the appointment of a new Chief Financial Officer in a separate filing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148394372","isCrawlerRequest":true}